Spyre Therapeutics, Inc.

Ownership Transactions Reported by 27 Insiders

Symbol
SYRE on Nasdaq
Industry
Pharmaceutical Preparations
Location
221 Crescent Street, Building 23, Suite 105, Waltham, MA

Insiders trading volume in the past year

Spyre Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Fairmount Funds Management LLC Director $3.43M May 14, 2024
Scott L. Burrows Chief Financial Officer $3.28M -$522K -13.7% Sep 3, 2024
Jeffrey W. Albers Director $1.01M -$257K -20.4% Nov 6, 2024
Anthony G. Quinn President & CEO, Director $580K Mar 16, 2022
Cameron Turtle Chief Executive Officer, Director $530K Feb 15, 2024
Marcio Souza Director $63.9K Aug 25, 2022
Hunter Smith Director Jun 22, 2023
Baker Bros. Advisors Lp Director Jun 8, 2021
Alison Frances Lawton Director Jun 22, 2023
Russell J. Cox Director Jun 22, 2023
Armen Shanafelt Director Jun 7, 2022
Ivana Magovcevic-Liebisch Director Jun 22, 2023
Steven Weber VP, Controller&Princ Acctg Off Feb 17, 2022
V. Bryan Lawlis Director Jun 7, 2022
James Paul Kastenmayer General Counsel Feb 23, 2023
Linda L. Neuman Chief Medical Officer Feb 23, 2023
Jeff Marc Goldberg President and CEO, Director Nov 29, 2022
Jonathan Alspaugh President and CFO Jun 22, 2023
Jr. Michael Conick Hanley Chief Business Officer Feb 23, 2023
Leslie Sloan Chief Operating Officer Aug 23, 2022
Sandesh Mahatme Director Jun 7, 2022
Laurie Stelzer Director May 14, 2024
Michael Henderson Director May 14, 2024
Sandra Milligan Director May 14, 2024
Mark C. McKenna Director Feb 1, 2024
Sheldon Sloan Chief Medical Officer Oct 1, 2024
Heidy King-Jones Chief Legal Officer and Corporate Secretary Feb 1, 2024

Recent Insider Transactions by Companies or Individuals for Spyre Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.